Analysts Weigh In on Green Thumb Industries, Doximity, and BioLife Solutions

Analysts weigh in on Green Thumb Industries (GTBIF), Doximity (DOCS), and BioLife Solutions (BLFS). GTBIF has a Buy rating with a $13.29 price target, implying a 94% upside from current levels. DOCS has a Hold rating with a $67.69 price target, implying a 7.4% upside. BLFS has a Buy rating with a $30.39 price target, implying a 38.3% upside.

Analysts have weighed in on the stock performance of Green Thumb Industries (GTBIF), Doximity (DOCS), and BioLife Solutions (BLFS), offering varying recommendations and price targets. GTBIF received a strong "Buy" rating with a price target of $13.29, indicating a significant 94% upside from current levels. DOCS was given a "Hold" rating with a price target of $67.69, suggesting a 7.4% upside. Meanwhile, BLFS was also rated "Buy" with a price target of $30.39, implying a 38.3% upside.

Green Thumb Industries, a leading cannabis consumer packaged goods company, has been the subject of analyst interest due to its recent earnings and market positioning. The company reported a 4.7% year-over-year (YoY) revenue growth in the second quarter of 2025, despite persistent pricing pressure in key markets. Adjusted EBITDA of $82.7 million and operating cash flow of $56 million underscored the company's financial resilience [2]. The company also repurchased 5.6 million shares, signaling a commitment to shareholder value. Analysts have highlighted Green Thumb's strong market share gains in states like Illinois, Pennsylvania, and Florida, as well as its preparation for the imminent adult-use launch in Minnesota.

Doximity, a healthcare technology company, received a "Hold" rating with a price target of $67.69. The company has been navigating challenges in the healthcare technology sector, with analysts noting that while the market potential is substantial, the execution and competitive landscape remain uncertain.

BioLife Solutions, a biotechnology company, was rated "Buy" with a price target of $30.39. The company has shown promise in the biotech sector, with analysts highlighting its innovative product pipeline and potential for growth. However, the sector's volatility and regulatory uncertainties are factors that analysts are closely monitoring.

These ratings and price targets reflect the analysts' assessments of each company's current valuation and future prospects. Investors should consider these ratings alongside their own research and risk tolerance when making investment decisions.

References:
[1] https://www.tipranks.com/stocks/tse:gtii
[2] https://www.stocktitan.net/news/GTBIF/green-thumb-industries-reports-second-quarter-2025-gimpk3wx7cmr.html